HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
Read original at benzingaStocks · News reference
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 10:40 AM
- Checked
- Jul 15, 2026, 10:40 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — CervoMed Inc. (CRVO)
Filed: 2026-08-10 AccNo: 0001437749-26-026771 Size: 207 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarCanaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.
Read original at benzingaCervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the
Read original at benzinga